Actavis Buys Durata In Bolt-On Deal, Leaves Room For Transformation
This article was originally published in The Pink Sheet Daily
Executive Summary
Actavis snaps up Durata for less than $1 billion, with significant contingent value tied to success of antibiotic Dalvance; meanwhile Actavis will likely continuing pursuing M&A.